Acute disseminated encephalomyelitis (ADEM) is an acute, immune-mediated disorder involving inflammation and demyelination in the central nervous system. It typically produces neurological symptoms affecting several areas of the brain, together with encephalopathy—an alteration in consciousness, behavior, or mental functioning. ADEM occurs most often in children, frequently after an infection, and usually follows a monophasic course, meaning a single clinical episode rather than repeated attacks.
Epidemiology and triggers
ADEM is uncommon. Estimates of its incidence vary among populations and studies, partly because diagnostic definitions and case ascertainment differ. It predominantly affects children, especially those of preschool and primary-school age, but can occur in adults.
A respiratory or gastrointestinal infection often precedes neurological symptoms by days to several weeks. In some cases, no preceding illness is identified. ADEM is generally understood as an immune-mediated complication rather than the direct invasion of nervous tissue by the preceding infectious organism.
Cases have also been reported after vaccination. However, an event occurring after a vaccine does not by itself establish that vaccination caused it, and causal evidence differs among vaccines and settings. Infections themselves are recognized triggers of ADEM, including historically important associations with measles.
Mechanisms and pathology
The defining tissue injury involves damage to myelin, the insulating material surrounding many nerve fibers. Myelin supports rapid electrical signaling; its disruption can impair communication across multiple neurological pathways.
The precise initiating mechanism is not fully established. Proposed mechanisms include an immune response to infection that cross-reacts with components of the nervous system and inflammatory activation that disrupts the blood–brain barrier. These mechanisms are not demonstrated in every individual case.
Characteristic histopathological findings include inflammatory cells around small veins and surrounding areas of myelin loss. Lesions predominantly involve white matter, but deep gray matter and other structures may also be affected. Tissue sampling is rarely necessary because diagnosis generally relies on the clinical course, imaging, and laboratory investigations.
Relationship to MOG antibody-associated disease
Some patients with an ADEM presentation have antibodies against myelin oligodendrocyte glycoprotein, a protein on the outer surface of central nervous system myelin. In the appropriate clinical setting, these findings can establish MOG antibody-associated disease (MOGAD).
ADEM describes a clinical syndrome, whereas MOGAD identifies an antibody-associated disease that can produce several syndromes. ADEM is a common MOGAD presentation in younger children, but not all ADEM is MOG antibody-positive. MOGAD may remain monophasic or subsequently cause further attacks, including optic neuritis or spinal cord inflammation.
Clinical features
Symptoms usually develop over hours to days. A preceding illness may be followed by fever, headache, vomiting, or lethargy before the neurological abnormalities become prominent.
The characteristic presentation combines:
- Encephalopathy: unusual irritability, confusion, marked sleepiness, behavioral change, or reduced consciousness.
- Multifocal neurological deficits: weakness, impaired coordination, difficulty walking, visual disturbances, speech abnormalities, or sensory changes.
- Possible seizures: ranging from individual seizures to prolonged or recurrent events.
- Spinal cord involvement: weakness, sensory disturbance, or bladder and bowel dysfunction when the spinal cord is affected.
The brainstem and cerebellar pathways may also be involved. Severe cases can cause profound impairment of consciousness, respiratory compromise, or substantial brain swelling.
Encephalopathy is required by widely used pediatric consensus definitions and should not be explained solely by fever. These definitions were developed for children; adult diagnosis is less standardized.
Diagnosis
There is no single test that independently confirms ADEM. Diagnosis integrates the clinical presentation, imaging, exclusion of competing causes, and the subsequent disease course.
Magnetic resonance imaging
Magnetic resonance imaging typically shows multiple, often large and poorly demarcated lesions in cerebral white matter. Lesions may also occur in the thalamus, basal ganglia, brainstem, cerebellum, and spinal cord. They are generally bright on T2-weighted and fluid-attenuated inversion recovery images; contrast enhancement is variable.
Imaging findings alone are not specific for ADEM. Follow-up imaging helps assess lesion resolution and determine whether new disease activity has occurred.
Cerebrospinal fluid and antibody testing
Examination of cerebrospinal fluid may show a mild increase in white blood cells or protein, but results can be normal. Testing also helps investigate infectious causes of encephalitis. Cerebrospinal fluid oligoclonal bands, commonly associated with multiple sclerosis, are less typical of ADEM and may be transient when present.
Serum MOG antibody testing using an appropriate cell-based assay can help classify compatible presentations. Antibody results require interpretation alongside clinical and imaging findings; a positive result alone is not sufficient to establish the diagnosis.
Clinical course
Under pediatric consensus criteria, ADEM is a first multifocal inflammatory demyelinating event with encephalopathy and characteristic brain MRI abnormalities. The absence of new clinical or MRI findings three months or more after onset supports a monophasic ADEM diagnosis. Symptoms or imaging changes during the initial three months may still belong to the original episode.
Differential diagnosis
The principal differential diagnoses include:
- Infectious encephalitis: can produce fever, altered consciousness, and seizures, and requires distinction from immune-mediated disease.
- Multiple sclerosis: more often presents without encephalopathy and may show characteristic lesion distributions or subsequent disease activity.
- MOGAD and neuromyelitis optica spectrum disorder: antibody-associated disorders that may involve the optic nerves, spinal cord, and brain.
- Autoimmune encephalitis: may produce prominent behavioral changes, seizures, movement abnormalities, and impaired consciousness.
- Vascular, metabolic, and toxic disorders: can resemble inflammatory demyelination clinically or radiologically.
Acute hemorrhagic leukoencephalitis is a rare, fulminant inflammatory demyelinating disorder often considered a severe variant of ADEM. It is distinguished by hemorrhagic tissue injury and can progress rapidly.
Treatment and evidence limitations
Treatment is generally delivered in hospital and is directed at suppressing inflammation while managing neurological complications. High-dose intravenous corticosteroids are commonly used as initial therapy, often followed by an oral taper. Intravenous immunoglobulin or plasma exchange may be used for severe disease or an inadequate response to corticosteroids.
Supportive care can include seizure management, respiratory support, management of brain swelling, nutritional support, and rehabilitation for motor, communication, or cognitive difficulties.
The treatment evidence consists largely of observational studies, case series, and expert consensus rather than large randomized trials specific to ADEM. Regimens therefore vary, and treatment decisions depend on disease severity and the exclusion or concurrent management of infection.
Prognosis and follow-up
Many children recover substantially over weeks to months, although improvement may continue longer. Some have persistent weakness, coordination problems, seizures, fatigue, or cognitive and behavioral difficulties. Subtle effects on attention, processing speed, or school performance may remain even after an apparently good physical recovery. Severe cases can cause lasting disability or death; adult series generally report less favorable outcomes than pediatric series.
Follow-up clarifies both recovery and disease classification. A later demyelinating attack may indicate MOGAD, multiple sclerosis, or another relapsing disorder rather than monophasic ADEM. Long-term immunotherapy is not routinely part of treatment for an isolated monophasic episode; its use in relapsing disease depends on the underlying diagnosis.